Lung cancer therapeutics market is anticipated to witness lucrative growth in the coming six years primarily due to the steady increase in the incidences and prevalence of cancer cases. Lung cancer accounts for a larger share of the overall number of patients suffering with cancer. The Lung Cancer Association of America reported that in the U.S., it is expected that there will be 220,000 new cases of lung cancer diagnosed for the year 2015. Some other key drivers responsible for the expected growth of this market are an increasing use of tobacco products, growing median age of the global population and increasing concentrations of cancer inducing air contaminants due to growing air pollution.
To request a sample copy or view summary of this report, click the link below:
Of the two primary types of lung cancers, namely small cell and non-small lung cancer, small cell lung cancer is more dangerous due to the fact that there are no drugs present for its treatment and that the smaller size of cancer cells present in this type of cancer make it harder to be treated even by surgical intervention. The different segments of therapeutic which are available for management of lung cancer are drugs in pipeline, radiotherapy, chemotherapy and surgery. The larger share of the lung cancer therapeutic market is accounted for by surgical procedures owing to the higher rates of treatment success and lower chances of cancer recurrences.
To request a sample copy or view TOC of this report, click the link below:
Geographically, owing to the presence of a large patient base of lung cancer and the availability of technologically advanced healthcare infrastructure, North America accounted for the largest share of lung cancer therapeutics market for 2013. Furthermore, it is also expected that due to emerging developments in the healthcare and surgical treatment segments for oncology and presence of high unmet medical needs in the Asia Pacific countries such as India and China, the Asia Pacific region will provide lucrative opportunities for growth throughput the forecast period. The key participants in the lung cancer therapeutics market are Roche Diagnostics, Astra Zeneca, Agennix AG, Pfizer, Sanofi-Aventis, Eli Lilly and Merck
About Grand View Research
Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.
For more information, visit http://www.grandviewresearch.com/
Corporate Sales Specialist, USA
Grand View Research, Inc